BioSpace News Archive

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Elizabeth (Liz) Kwo, MD, Staff Vice President, Clinical Data Analytics at Anthem, to its Board of Directors. “We are delighted to welcome Liz to our Board of Directors as her broad and deep background uniquely complements our existing skills and experiences,” said Michael Clayman, MD, President and Chief Executive Officer of Flexion Therapeutics. “We are confident

IND filing today for STI-1499 (COVI-GUARD™) for hospitalized COVID-19 patients. The initial trial is expected to be followed by pivotal trials with a goal of potentially receiving an EUA (Emergency Use Authorization) as early as the end of this year. Animal model data (Syrian Golden Hamsters infected with SARS-CoV-2) confirm the neutralizing profile and high potency of this antibody, expected effective dose in human to be at least 5 times lower than current known antibodies being assessed in

Today Lexogen, the transcriptomics and next-generation sequencing company, announced the launch of the QuantSeq-Pool Sample-Barcoded 3' mRNA-Seq Library Prep Kit. The QuantSeq-Pool method combines sample barcoding and early pooling with the benefits of Lexogen’s established QuantSeq 3' mRNA-Seq kit, which has been already cited in more than

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today is providing shareholders with a update on its COVID-19 initiatives including vaccine and real-time, breath-based mobile testing device as well as its dermatological therapy pipeline.

Sharps Compliance Corp., a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, reported financial results for the fourth quarter and fiscal year 2020, ended June 30, 2020.

Precision BioSciences, Inc. announced the U.S. Food and Drug Administration has granted Fast Track Designation to Precision for PBCAR0191, the company’s lead investigational allogeneic chimeric antigen receptor cell therapy for the treatment of advanced B-cell precursor acute lymphoblastic leukemia.

Turning Point Therapeutics, Inc., a precision oncology company developing next-generation therapies that target genetic drivers of cancer, reported early interim data from the registrational Phase 2 TRIDENT-1 study of lead drug candidate, repotrectinib, and announced recent regulatory feedback from the Food and Drug Administration on the TRIDENT-1 trial design.

Pluristem Therapeutics Inc., a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced it has completed patient enrollment in its Phase I study evaluating PLX-R18 as a treatment for incomplete hematopoietic recovery following hematopoietic cell transplantation, in the U.S. and in Israel.

Evogene Ltd., a leading computational biology company targeting to revolutionize life-science product development across several market segments including ag-biologicals, ag-chemicals, human microbiome based therapies and medical cannabis, announced that it will be presenting at the LD 500 investor conference on Wednesday, September 2nd at 9:40 AM ET.

Bio-Techne Corporation (NASDAQ:TECH), in partnership with Leica Biosystems, today announced the automation of RNAscope™ COVID-19 probes on BOND RX*, Leica’s staining platform, for research use only. Researchers now have the a